AIM ImmunoTech (LTS:0A4Y) Retained Earnings : $-420.86 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is AIM ImmunoTech Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. AIM ImmunoTech's retained earnings for the quarter that ended in Sep. 2024 was $-420.86 Mil.

AIM ImmunoTech's quarterly retained earnings declined from Mar. 2024 ($-415.33 Mil) to Jun. 2024 ($-417.16 Mil) and declined from Jun. 2024 ($-417.16 Mil) to Sep. 2024 ($-420.86 Mil).

AIM ImmunoTech's annual retained earnings declined from Dec. 2021 ($-361.10 Mil) to Dec. 2022 ($-380.55 Mil) and declined from Dec. 2022 ($-380.55 Mil) to Dec. 2023 ($-409.51 Mil).

AIM ImmunoTech Retained Earnings Historical Data

The historical data trend for AIM ImmunoTech's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Retained Earnings Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-327.57

-341.97

-361.10

-380.55

-409.51

AIM ImmunoTech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Retained Earnings	Get a 7-Day Free Trial															-396.93	-409.51	-415.33	-417.16	-420.86

AIM ImmunoTech Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

AIM ImmunoTech (LTS:0A4Y) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

AIM ImmunoTech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

AIM:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech Headlines

No Headlines